There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (NASDAQ: EPZM) and Achaogen (NASDAQ: AKAO) with bullish sentiments.
Epizyme (NASDAQ: EPZM)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Epizyme, with a price target of $25. The company’s shares closed yesterday at $14.45.
Fein commented:
“Valuation and risks. Our price target of $25 on Epizyme is based on a probability-adjusted sum-of-parts NPV-DCF: $21 EZH2 (NHL + INI-) + $1 DOT1L (MLL-R) + $3 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller- than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.1% and a 49.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Epizyme with a $24.38 average price target, a 68.7% upside from current levels. In a report issued on June 15, Cowen & Co. also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Achaogen (NASDAQ: AKAO)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Achaogen, with a price target of $19. The company’s shares closed yesterday at $9.59, close to its 52-week low of $8.73.
Arce observed:
“916-3963, POS Risk-adj value Full value Plazomicin – U.S. 100% $10.56 $10.56 Shares outstanding 44,796 Plazomicin – EU 85% $3.24 $3.81 Current share price $9.59 Discount rate 12.5% C-Scape – U.S.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 29.3% and a 48.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achaogen with a $18.75 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $20 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AKAO:
